Single Dose of DMT Rapidly Reduces Depression Symptoms in Clinical Trial

Psychedelic Breakthrough for Depression

A single intravenous dose of dimethyltryptamine, the powerful psychedelic compound found in ayahuasca, has shown remarkable promise as a rapid-acting treatment for major depressive disorder. The results of a phase IIa randomised placebo-controlled trial, published in Nature Medicine, reveal that the short-acting psychedelic produced significant and lasting reductions in depressive symptoms.

How the Trial Worked

The study, led by Doctor David Erritzoe of Imperial College London, enrolled thirty-four adults with moderate-to-severe major depressive disorder. Participants received a twenty-one point five milligram intravenous infusion of DMT, which produced a psychedelic experience lasting roughly twenty to thirty minutes. This short duration is a key clinical advantage over longer-acting psychedelics such as psilocybin, which requires six to eight hours of supervised therapy.

At the two-week mark, participants who received DMT showed significantly fewer depressive symptoms than those given a placebo. By three months, fifty-seven percent of participants who received a single dose had achieved full remission from depression.

A Surprising Finding on Dosing

Intriguingly, the study found no apparent difference in antidepressant effect between a one-dose and two-dose regimen. Participants who received one dose of placebo followed by one dose of DMT actually had fewer symptoms at fourteen weeks than those who received two doses of DMT, raising interesting questions about optimal dosing strategies.

Safety Profile and Expert Caution

Side effects were more common in the DMT group, with the most frequent being anxiety and nausea. No serious adverse events were reported. However, experts have urged caution in interpreting the results. The small sample size, limited ethnic diversity, and inability to fully blind participants to their treatment group mean that larger, more inclusive trials will be needed before DMT can be considered a validated depression treatment.

What Comes Next

The trial was sponsored by Small Pharma, now part of Cybin, which holds a proprietary pharmaceutical-grade formulation of DMT. With psychedelic-assisted therapy gaining momentum across the psychiatric research community, larger phase three trials will be critical in determining whether DMT can join the clinical toolkit for treating depression.